Related Experiment Videos
Pharmacological solutions for vitiligo: emerging role of Janus kinase inhibitors
Hristina Kocic1, Uwe Wollina2, Aleksandar Godic3,4
1Clinic for Dermatology University Clinical Center Nis, Medicl Faculty University Nis, Serbia.
Introduction:
Vitiligo is a chronic autoimmune condition characterized by progressive loss of melanocytes and the development of depigmented skin lesions. Increasing evidence highlights the pivotal role of dysregulated JAK-STAT signaling in disease pathogenesis.
Areas Covered:
A literature search was performed using PubMed/MEDLINE, to identify relevant studies published up to January 2026, about the contribution of JAK-STAT-dependent pathways to vitiligo progression, IFN-γ-induced chemokine production (CXCL9 and CXCL10), recruitment of cytotoxic CD8+ T lymphocytes, and the involvement of tissue-resident memory (T < sub > RM) T cells in maintaining localized immune responses. The effects of JAK inhibition across multiple cell populations, including melanocytes, keratinocytes, and immune cells were examined. Current clinical data regarding both topical and systemic JAK inhibitors in the context of targeted repigmentation strategies.
Expert Opinion:
Unlike conventional systemic immunosuppressive therapies, JAK inhibitors enable targeted modulation of specific inflammatory pathways central to vitiligo pathophysiology. Future therapeutic success will likely depend on appropriate patient selection, optimal timing of intervention, and rational combination approaches aimed at sustaining repigmentation and reducing relapse risk. Collectively, these developments support the emerging role of JAK-directed therapy as a significant advancement in the management of vitiligo.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
The JAK-STAT Signaling Pathway
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...